已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

医学 索拉非尼 甲状腺癌 内科学 安慰剂 实体瘤疗效评价标准 临床终点 肿瘤科 耐火材料(行星科学) 临床试验 癌症 甲状腺球蛋白 临床研究阶段 甲状腺 病理 肝细胞癌 物理 替代医学 天体生物学
作者
Marcia S. Brose,Christopher M. Nutting,Barbara Jarząb,Rossella Elisei,Salvatore Siena,Lars Bastholt,Christelle De La Fouchardière,Furio Pacini,Ralf Paschke,Young Kee Shong,Steven I. Sherman,Johannes W. A. Smit,John Chung,Christian Kappeler,Carol Peña,István Molnár,Martin Schlumberger
出处
期刊:The Lancet [Elsevier]
卷期号:384 (9940): 319-328 被引量:1378
标识
DOI:10.1016/s0140-6736(14)60421-9
摘要

Patients with radioactive iodine ((131)I)-refractory locally advanced or metastatic differentiated thyroid cancer have a poor prognosis because of the absence of effective treatment options. In this study, we assessed the efficacy and safety of orally administered sorafenib in the treatment of patients with this type of cancer.In this multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (DECISION), we investigated sorafenib (400 mg orally twice daily) in patients with radioactive iodine-refractory locally advanced or metastatic differentiated thyroid cancer that had progressed within the past 14 months. Adult patients (≥18 years of age) with this type of cancer were enrolled from 77 centres in 18 countries. To be eligible for inclusion, participants had to have at least one measurable lesion by CT or MRI according to Response Evaluation Criteria In Solid Tumors (RECIST); Eastern Cooperative Oncology Group performance status 0-2; adequate bone marrow, liver, and renal function; and serum thyroid-stimulating hormone concentration lower than 0·5 mIU/L. An interactive voice response system was used to randomly allocate participants in a 1:1 ratio to either sorafenib or matching placebo. Patients, investigators, and the study sponsor were masked to treatment assignment. The primary endpoint was progression-free survival, assessed every 8 weeks by central independent review. Analysis was by intention to treat. Patients in the placebo group could cross over to open-label sorafenib upon disease progression. Archival tumour tissue was examined for BRAF and RAS mutations, and serum thyroglobulin was measured at baseline and at each visit. This study is registered with ClinicalTrials.gov, number NCT00984282, and with the EU Clinical Trials Register, number EudraCT 2009-012007-25.Patients were randomly allocated on a 1:1 basis to sorafenib or placebo. The intention-to-treat population comprised 417 patients (207 in the sorafenib group and 210 in the placebo group) and the safety population was 416 patients (207 in the sorafenib group and 209 in the placebo group). Median progression-free survival was significantly longer in the sorafenib group (10·8 months) than in the placebo group (5·8 months; hazard ratio [HR] 0·59, 95% CI 0·45-0·76; p<0·0001). Progression-free survival improved in all prespecified clinical and genetic biomarker subgroups, irrespective of mutation status. Adverse events occurred in 204 of 207 (98·6%) patients receiving sorafenib during the double-blind period and in 183 of 209 (87·6%) patients receiving placebo. Most adverse events were grade 1 or 2. The most frequent treatment-emergent adverse events in the sorafenib group were hand-foot skin reaction (76·3%), diarrhoea (68·6%), alopecia (67·1%), and rash or desquamation (50·2%).Sorafenib significantly improved progression-free survival compared with placebo in patients with progressive radioactive iodine-refractory differentiated thyroid cancer. Adverse events were consistent with the known safety profile of sorafenib. These results suggest that sorafenib is a new treatment option for patients with progressive radioactive iodine-refractory differentiated thyroid cancer.Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals (an Amgen subsidiary).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
蝈蝈发布了新的文献求助20
1秒前
哒哒哒完成签到,获得积分10
3秒前
lll发布了新的文献求助10
9秒前
9秒前
11秒前
12秒前
支凤妖发布了新的文献求助10
15秒前
太阳完成签到,获得积分10
15秒前
光亮的妖妖完成签到,获得积分10
16秒前
roking完成签到,获得积分10
17秒前
情怀应助深情的友易采纳,获得10
19秒前
JJ应助大胆翎采纳,获得50
20秒前
鳗鱼如松完成签到,获得积分10
21秒前
22秒前
23秒前
完美世界应助大老虎采纳,获得10
24秒前
knose完成签到,获得积分10
24秒前
25秒前
芝芝霉霉应助lll采纳,获得10
26秒前
爆米花应助胡胡胡upupup采纳,获得10
28秒前
yuzhou完成签到,获得积分10
28秒前
鳗鱼如松发布了新的文献求助10
30秒前
SamSimple发布了新的文献求助10
30秒前
华仔应助yuzhou采纳,获得10
32秒前
32秒前
受伤代容发布了新的文献求助10
37秒前
科研通AI2S应助asdadadad采纳,获得10
39秒前
JinkFun发布了新的文献求助10
40秒前
斯文败类应助俞若枫采纳,获得30
41秒前
整齐的含灵应助muyu采纳,获得10
45秒前
45秒前
zhaoxiao完成签到 ,获得积分10
48秒前
陶醉寒荷发布了新的文献求助10
48秒前
49秒前
香菜不明白完成签到,获得积分10
50秒前
51秒前
yuzhou发布了新的文献求助10
51秒前
天天快乐应助婉玉采纳,获得10
52秒前
机智的宝贝完成签到,获得积分20
53秒前
俞若枫发布了新的文献求助30
53秒前
高分求助中
Sustainability in Tides Chemistry 2000
The ACS Guide to Scholarly Communication 2000
Studien zur Ideengeschichte der Gesetzgebung 1000
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Threaded Harmony: A Sustainable Approach to Fashion 810
Pharmacogenomics: Applications to Patient Care, Third Edition 800
Free Will in the Flesh 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3081353
求助须知:如何正确求助?哪些是违规求助? 2734041
关于积分的说明 7531449
捐赠科研通 2383454
什么是DOI,文献DOI怎么找? 1263852
科研通“疑难数据库(出版商)”最低求助积分说明 612420
版权声明 597560